Daniel Hartnett, associate managing director of the Compliance Risk & Diligence Practice of Kroll, advises on the steps that pharmaceutical companies should take to reduce the risk of dealing with third parties, as they develop a COVID-19 vaccine.
Isabelle Glimcher, a fellow at the NYU Stern Center for Business and Human Rights, recommends six steps that government procurement officials should be taking to prevent workers’ rights abuses by suppliers.
Suresh Acharya, Professor of Practice at the University of Maryland’s Robert H. Smith School of Business, lays out the challenges of creating an end-to-end supply chain that can produce and distribute millions of doses of a vaccine for COVID-19.
Rosemary Coates, executive director of The Reshoring Institute, explains why the coronavirus pandemic might finally be the crisis that drives manufacturers to shift production from China back to the U.S.
Patrick Thielen, senior vice president of financial lines with Chubb, explains why malware attacks are on the rise, and what manufacturers must do to protect their people and systems from cyber criminals.
Ann Marie Uetz, head of the coronavirus task force with the law firm of Foley & Lardner LLP, discusses the results of a pair of surveys about how executives are responding to supply-chain disruptions caused by the pandemic and rising geopolitical tensions.